Unwinding Fibrosis in Peyronie's Disease by Ilg, Marcus M. & Cellek, Selim
Expert Opinion
Unwinding Fibrosis in Peyronie's Dis[Instruction: 
Latest in Peyronie's Disease
[PGN: Set as RRH.]]ease
Fibrosis is defined as the excess accumulation of extracellular matrix proteins in response to chronic injury or 
inflammation. 
1
 Peyronie's disease (PD) is a fibrotic disorder affecting the penile tunica albuginea (TA), 
characterized by the formation of a plaque that may lead to pain, curvature, or erectile dysfunction. 
2
 The first 
observation of PD dates back to 1,561, when it was reported by Fallopius and Vesalius, but it was the French 
surgeon to King Louis XV, Francois Gigot de la Peyronie, after whom the disease was named because of his 






 Despite 276 years of knowledge of PD, the genetic basis of the disease is yet to be 
fully understood,
5
 while much progress has been made in understanding the fibrotic process in general and in 
PD. 
6
 PD has been described to have 2 distinct phases: an acute (unstable, inflammatory) phase associated with 
penile pain and worsening penile deformity due to plaque development and a chronic (stable) phase typically 







 Reports have suggested the prevalence of PD to range between 0.3% and 9%. 
9–11
 Surgical 
treatment is considered to be the gold standard in patients with stable and painless PD for a period of at least 
6 months to correct curvature to allow successful intercourse, despite the risks of penile shortening, erectile 
dysfunction, or penile numbness as well as recurrence of curvature. 
12–14
 Although there has been a significant 
unmet need to develop novel non-surgical, oral therapeutics, all the attempts have failed so far. The only non-
surgical treatment that has been approved by the Food and Drug Administration for PD in men with more than 
30° and less than 90° of penile curvature is collagenase clostridium histolyticum (an enzyme that specifically 
breaks down collagen), which needs to be administered by injection into the plaque. 
15
 
PD is not the only fibrotic disease that suffers from lack of successful drug development; apart from idiopathic 
pulmonary fibrosis for which 2 drugs have been approved (pirfenidone and nintedanib  
16
 ), the drug 
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development efforts have been unsuccessful in fibrosis arena. Several review papers have discussed why and 
how this happened.
6 , 16–21
 In the PD field, the lack of translational success from preclinical to clinical studies 
can be partly explained by the following three factors:
1. An early open-label study with tamoxifen
22
 showed clinical efficacy in patients who were in 
early stages of the disease. However, a later placebo-controlled randomized clinical trial failed 
to show an efficacy where most of the patients included were at the late stage.
23
 This highlights 
the difference between the early and late stages. Tamoxifen may not be able to reverse the 
existing fibrosis but may prevent the formation of new fibrotic lesion, which is accordance with 
preclinical evidence for tamoxifen's ability to prevent not reverse fibrosis.
24
 Several preclinical 
studies (including ours) are aimed at developing novel medicines using preclinical models, 
which are limited to early stages of PD. For example, the most frequently used animal model of 
PD uses transforming growth factor (TGF)–beta injection into the penis of rats, and the novel 
drugs are administered often immediately after the TGF injection. The effect of novel drugs on 
established (ie, late stage) PD is difficult to test in this animal model because the plaque is 
known to resolve spontaneously. In other words, most of the drug development efforts have 
concentrated on the prevention of fibrosis rather than the reversal, whereas the clinical trials 
were designed to look for a reversal effect.
2. Most of the drug development efforts have been based on a single-target approach. This 
involves picking a single molecular target, for which small molecule ligands are developed. The 
best drug-like ligand is then taken through preclinical and clinical development phases. This 
candidate molecule then fails at phase II clinical study owing to lack of efficacy, although the 
results from preclinical studies including animal models have been encouraging. We are 
proposing that the reason behind the failure of the single-target approach in PD or fibrosis lays 
within the pathophysiology of fibrosis. Fibrosis is actually an aberrant form of wound healing, 
which is one of the strongest, most evolved and most conserved protective mechanisms in the 
human body.
25
 The evolution has programmed several buffering systems into the wound 
healing mechanism; if one pathway fails, another “compensatory” pathway can take over. One 
can think of wound healing as a machine with several safety fall-back valves. When a single 
target is hit by a new drug, the machine can then activate another pathway to compensate for 
the lost function. It is then not surprising that these drug candidates fail in phase II clinical 
efficacy studies as the compensatory mechanisms are active in full force.
3. Development of novel therapeutic approaches for PD is hampered by the lack of inexpensive, 
reproducible, and consistent animal models that mirror the clinical aspects of the disease – most 
importantly curvature formation and ossification.
26





 and surgical trauma to TA
29
; however, neither 
significant curvature nor ossification was achieved. Repeated administration of TGF-beta is 
required to achieve significant curvature.
30
 The Tsk genetic mouse has achieved curvature and 
cartilage formation but is an expensive model and the fibrosis is not limited to TA.
31
 Although 
allograft TA transplantation in rats has been shown to achieve both significant curvature and 
some signs of ossification,
32
 this is again a quite expensive and elaborate animal model, which 
involves tissue transplantation. Most of the currently available animal models suffer from 
spontaneous resolution of the fibrosis, which makes long-term drug dosing studies or reversal 
of fibrosis attempts difficult.
Based on the aforementioned rather gloomy landscape, what can we do as preclinical and clinical scientists? 
Here are some suggestions:
1. Better clinical study design: Keeping in mind the notion of prevention versus reversal, we need 
to ensure that our clinical studies are designed to reflect the mode of action of the candidate 
drugs and to include the right patient for the right drug. A drug that is supposed to prevent 
plaque formation should only be tested on early stage patients without stable plaques, while a 
plaque-dissolving drug should only be tested on stable plaques. We should also ensure that any 
clinical trial with oral drugs should be placebo controlled particularly, given the significant 
variability in the natural history of the condition. It should be noted that recruitment of patients 
at early stage PD has always been difficult.
2. Better animal models: We need better animal models for PD that are true representatives of 
human pathology and that can be used for “reversal” type of studies.
3. Phenotypic screening rather than the single-target approach: Instead of the single-target 
approach, we can try to develop new drugs for PD using the phenotypic approach. The term 
phenotypic approach refers to phenotypic drug discovery (as opposed to the single target-based 
approach described earlier). Phenotypic drug discovery has been proven to be more effective in 
identifying new first-in-class drugs. 
33
 Phenotypic screening is thought to be more biologically 
and disease relevant in modulating a certain pathological phenotype opposed to an isolated 
pathway. 
34
 For this approach to drug discovery, a disease-relevant phenotype is vital. 
35
 In this 
approach, rather than picking a single target, a phenotype is selected, and the drugs are tested 
on the phenotype rather than the target. This approach has actually been shown to be more 
effective than the single-target approach when all Food and Drug Administration–approved 
drugs are analyzed. 
33
 We have recently identified a combination of phosphodiesterase type 5 
inhibitors and selective estrogen receptor modulators from an in  vitro phenotypic screen 
campaign using the myofibroblast as phenotype. 
24
 
4. Better understanding of PD pathophysiology: We need to understand the pathophysiology of 
PD better. How can an established plaque be eliminated? What are the compensatory 
mechanisms? What is the line that separates acute and chronic phase?
We have still much work to do on PD and all the other fibrotic diseases. Fibrosis remains a significant 
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